![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
![[thumbnail of 7016oa.pdf]](https://edoc.mdc-berlin.de/style/images/fileicons/application_pdf.png) |
PDF
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
589kB |
| Item Type: | Article |
|---|---|
| Title: | Cellular senescence in cancer treatment: friend or foe? |
| Creators Name: | Kahlem, P., Doerken, B. and Schmitt, C.A. |
| Abstract: | Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention. |
| Keywords: | Antineoplastic Agents, Apoptosis, Cell Aging, Tumor Cell Line, Cyclin-Dependent Kinase Inhibitor p16, DNA, DNA Damage, Biological Models, Neoplasms, Tumor Suppressor Protein p53, Animals |
| Source: | Journal of Clinical Investigation |
| ISSN: | 0021-9738 |
| Publisher: | American Society for Clinical Investigation |
| Volume: | 113 |
| Number: | 2 |
| Page Range: | 169-174 |
| Date: | January 2004 |
| Official Publication: | https://doi.org/10.1172/JCI20784 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
